Incannex Healthcare (IXHL) Liabilities and Shareholders Equity (2020 - 2026)
Incannex Healthcare's (IXHL) quarterly Liabilities and Shareholders Equity came in at $80.3 million in Q1 2026, up 395.67% year-on-year from $16.2 million in Q1 2025, and up 7.04% quarter-over-quarter from $75.0 million in Q4 2025.
Incannex Healthcare (IXHL) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Incannex Healthcare has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $80.3 million for Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $80.3 million, up 395.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $254.5 million (up 321.3% YoY), and the FY2025 annual result was $20.4 million, up 19.94% from the prior year.
- Liabilities and Shareholders Equity came in at $80.3 million for Q1 2026 at Incannex Healthcare, up from $75.0 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $80.3 million in Q1 2026 to a low of $11.1 million in Q4 2024.
- The 5-year median for Liabilities and Shareholders Equity is $21.4 million (2023), against an average of $34.7 million.
- Across the five-year window, Liabilities and Shareholders Equity tumbled 50.33% in 2024 and jumped 575.36% in 2025, its largest moves.
- Incannex Healthcare's Liabilities and Shareholders Equity stood at $37.9 million in 2022, then slumped by 40.97% to $22.4 million in 2023, then plunged by 50.33% to $11.1 million in 2024, then surged by 575.36% to $75.0 million in 2025, then grew by 7.04% to $80.3 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $80.3 million (Q1 2026), $75.0 million (Q4 2025), and $78.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 2.27 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.35 Bn |
| 10 | Incannex Healthcare | 45.81 Mn | 45.81 Mn | - | 80.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.28 Mn |
| Dec 31, 2025 | 75.01 Mn |
| Sep 30, 2025 | 78.72 Mn |
| Jun 30, 2025 | 20.45 Mn |
| Mar 31, 2025 | 16.20 Mn |
| Dec 31, 2024 | 11.11 Mn |
| Sep 30, 2024 | 16.05 Mn |
| Jun 30, 2024 | 17.05 Mn |
| Mar 31, 2024 | 17.25 Mn |
| Dec 31, 2023 | 22.36 Mn |
| Jun 30, 2023 | 23.78 Mn |
| Jun 30, 2022 | 37.88 Mn |
| Jun 30, 2021 | 9.33 Mn |
| Jun 30, 2020 | 4.24 Mn |